Mohs Micrographic Surgery Use in the United States Based on Medicare Data

To the Editor I read with great interest the excellent article by Adamson and Dusetzina¹ published in the January 2017 issue of JAMA Dermatology.¹ The authors note that 55% of surgically treated nonmelanoma skin cancers were treated with Mohs micrographic surgery (MMS), while excisions and electrodessication and curettage accounted for 16.2% and 28.8% of procedures, respectively. However, the authors’ suggestions that these numbers are inconsistent with the Appropriate Use Criteria (AUC) for MMS,² and their implication that these data suggest MMS overuse, merit additional context and comment.